Key result
The presence of visible coronary collaterals in patients with acute coronary syndromes did not significantly affect the 1-year risk of major adverse cardiac events compared to no collaterals (HR 0.94; 95% CI 0.76-1.16; p=0.55).
Why the study?
Does the presence of visible coronary collaterals improve clinical outcomes in patients with moderate to high risk acute coronary syndromes?
RCT (n=5,412)
Does the presence of visible coronary collaterals improve clinical outcomes in patients with moderate to high risk acute coronary syndromes?
In contrast to prior studies, the presence of visible coronary collaterals does not confer a prognostic benefit in patients with moderate to high-risk acute coronary syndromes.
Answers are grounded in this paper and cite their sources.
Does not support using visible collaterals for prognostication in moderate- to high-risk ACS; challenges prior observational reports and leaves the role open for prospective study.
OBJECTIVE: We sought to assess the prognostic role of collaterals in a large population of patients presenting with an acute coronary syndrome (ACS). METHODS: The coronary collateral circulation was assessed by an independent angiographic core laboratory using the Rentrop Score in patients enrolled in the randomised Acute Catheterization and Urgent Intervention Triage Strategy trial. RESULTS: The cohort comprised 5412 patients with moderate to high risk ACS. A total of 858 patients (16.0%) had visible collaterals while 4554 patients (84.0%) had no collaterals. After multivariable adjustment, there were no differences in clinical outcomes at 1 year between the groups, including major adverse cardiac events (MACE) (HR 0.94 (95% CI 0.76 to 1.16), p=0.55), mortality (HR 1.03 (0.65 to 1.62), p=0.91), myocardial infarction (MI) (HR 1.07 (0.83 to 1.38), p=0.60) and unplanned target vessel revascularisation (TVR) (HR 0.95 (0.71 to 1.28), p=0.75). Similarly, in the subgroup of patients undergoing percutaneous coronary intervention (PCI), the adjusted HR for major adverse cardiac events was 1.1 (0.76 to 1.61), p=0.595; 0.81 (0.10 to 6.44), p=0.999 for mortality; and 0.86 (0.54 to 1.35), p=0.564 for MI. The risk of unplanned TVR was increased (HR 2.74 (1.48 to 5.10), p=0.004). CONCLUSIONS: In contrast to other studies, this large core laboratory-based analysis does not confirm a beneficial role of visible coronary collateral vessels on clinical outcomes in patients with ACS; the presence of collaterals was even associated with increased mortality in the unadjusted analysis. Collaterals were associated with a higher risk of TVR in patients undergoing PCI, a finding that may not have been fully corrected given confounders and clinical differences between the groups. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00093158.
No takes yet. Share an insight, caveat, or question.
Meier et al. (2013) conducted an RCT in acute coronary syndrome (n=5,412). Visible coronary collaterals vs. No visible collaterals was evaluated on major adverse cardiac events (MACE) (HR 0.94, 95% CI 0.76-1.16, p=0.55). The presence of visible coronary collaterals in patients with acute coronary syndromes did not significantly affect the 1-year risk of major adverse cardiac events compared to no collaterals (HR 0.94; 95% CI 0.76-1.16; p=0.55).
Synapse has enriched 10 related papers. Consider them for comparative context: